The New York Times - Business:
Many middle-income countries are left out of the deal, widening a gulf in access to critical medicines.
This post first appeared in The New York Times - Business. Read the original article.
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
